Ctrl K
Last 39 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.57 | 30.63 | 3.16 | 2.00 | 3.59 | — | 51.46 | 55.92 | 55.00 | 82.25 | 56.57 | 34.28 | 42.26 | 24.12 | 20.54 | 13.64 | 18.12 | 19.85 | 27.73 | 18.19 | 24.07 |
| — | — | -93.9% | -96.4% | -93.5% | — | -9.0% | +63.1% | +30.1% | +241.0% | +175.4% | +151.4% | +133.3% | +21.5% | -25.9% | -25.0% | -24.7% | -86.8% | — | — | -85.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -587.6% | -28.4% | -115.5% | -209.2% | -202.9% | -928.5% | -134.4% | -83.1% | -50.4% | -51.7% | -35.5% | -29.2% | -23.1% | -16.3% | -18.6% | -14.0% | -12.0% | -12.0% | -9.7% | -8.7% | -12.9% |
| — | +96.9% | +14.1% | -151.8% | -302.3% | -1695.1% | -278.4% | -184.4% | -118.3% | -217.3% | -91.3% | -108.5% | -93.2% | -35.5% | -91.1% | -61.1% | +7.6% | -52.9% | — | -0.7% | -43.7% | |
| ROA | -250.5% | -25.3% | -44.2% | -100.5% | -43.5% | -85.4% | -71.1% | -53.0% | -37.5% | -42.1% | -29.4% | -24.5% | -20.3% | -14.8% | -16.6% | -12.5% | -10.7% | -10.8% | -8.7% | -7.6% | -10.5% |
| — | +70.3% | +37.8% | -89.4% | -15.9% | -102.7% | -141.6% | -116.7% | -84.8% | -185.4% | -77.1% | -95.8% | -88.9% | -36.8% | -91.7% | -64.0% | -2.1% | -166.0% | +49.6% | -27.7% | -56.4% | |
| ROIC | — | -76.0% | — | — | — | — | — | — | — | — | — | — | -111.6% | -25.3% | -22.5% | -17.0% | -14.3% | -35.0% | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | -679.7% | +27.9% | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.00 | — | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| — | — | — | — | -89.5% | — | +29.9% | +47.2% | +40.6% | +82.4% | +46.5% | +343.5% | +240.6% | +181.0% | +152.1% | -30.7% | — | -90.8% | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.51 | 19.48 | 2.34 | 1.51 | 2.88 | 0.75 | 1.90 | 1.95 | 3.42 | 3.88 | 6.70 | 5.05 | 7.12 | 9.45 | 12.15 | 7.94 | 10.27 | 9.18 | 10.03 | 8.77 | 7.59 |
| — | +2485.6% | +23.1% | -22.5% | -15.7% | -80.6% | -71.6% | -61.3% | -52.0% | -58.9% | -44.9% | -36.4% | -30.7% | +2.9% | +21.1% | -9.5% | +35.4% | +165.8% | +1069.2% | +920.8% | +95.2% | |
| Quick Ratio | 1.51 | 19.48 | 2.34 | 1.51 | 2.88 | 0.75 | 1.90 | 1.95 | 3.42 | 3.88 | 6.70 | 5.05 | 7.12 | 9.45 | 12.15 | 7.94 | 10.27 | 9.18 | 10.03 | 8.77 | 7.59 |
| — | +2485.6% | +23.1% | -22.5% | -15.7% | -80.6% | -71.6% | -61.3% | -52.0% | -58.9% | -44.9% | -36.4% | -30.7% | +2.9% | +21.1% | -9.5% | +35.4% | +165.8% | +1069.2% | +920.8% | +95.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 39 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INDP stock.
Indaptus Therapeutics, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Indaptus Therapeutics, Inc.'s business trajectory between earnings reports.